About Biostem Technologies Inc
- Industry: Pharmaceuticals
- Exchange: OTC MARKETS
- Country: US
- Website: https://www.biostemtechnologies.com/
Frequently Asked Questions
What is the 52-week range for BSEM?
The 52-week high is $8.4 and the 52-week low is $2.251.
What is the P/E ratio for BSEM?
The P/E ratio data is currently unavailable.
What is the dividend yield for BSEM?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -47.03%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -13.08%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.59.
Analyst Recommendation Trends
Wall Street analyst consensus for BSEM over the last few months:
Latest BSEM News
BioStem Technologies Files Prospectus Related To The Resale Of Up To 2.2M Shares By Selling Stockholders
-SEC Filing
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
Newly issued U.S. Patent and pending allowances in the U.S. and Mexico extend protection for the company's sterile placental allograft, micronized wound care, and umbilical cord extract technologiesPOMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the Unite
BioStem Secures US Patent, Additional US And Mexico Allowances For Tissue Technologies
BioStem Technologies, Inc. (NASDAQ:BSEM) ("BioStem" or the "Company"), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of the Company’s common stock, Series A warrants to purchase up to an aggregate of 735,296 shares of common stock and Ser
Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform
West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform. BioStem Technologies will utilize Terminal1’s integrated suite of shareholder intelligence, investor communications, and digital investor relations tools, giving the company a centralized platform to better understand its shareholder base, communicate with investors, and measure engagement
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular session. The market value of their outstanding shares is at $1.0 million. SkyAI (NASDAQ:SKYA) stock rose 20.43% to
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
POMPANO BEACH, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a $40 million Committed Equity Facility (the “CEF”) with Roth Principal Investments, LLC (“Roth”), an affiliate of CR Financial Holdings, Inc., the holding company for Roth Capital Partners.
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
Additions extend BioStem's hospital channel to its BioRetain® wound care linePOMPANO BEACH, Fla., Sept. 04, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that VENDAJE® and VENDAJE AC® have been added to the Company's existing contracts with Vizient, Inc. and Premier, Inc., two of the nati
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-17 | SMITH-VAN VURST ANDREW | -9,574 | - | - |
| 2026-09-17 | SMITH-VAN VURST ANDREW | +9,574 | - | - |
| 2026-09-17 | Matuszewski Jason | -16,650 | - | - |
| 2026-09-17 | Matuszewski Jason | +16,650 | - | - |
| 2026-09-15 | POE BRANDON | -1,694 | - | - |
| 2026-09-15 | POE BRANDON | +1,694 | - | - |
| 2026-09-15 | SMITH-VAN VURST ANDREW | -7,622 | - | - |
| 2026-09-15 | SMITH-VAN VURST ANDREW | +7,622 | - | - |
| 2026-09-15 | WARRINGTON KENNETH HOWARD JR | -1,694 | - | - |
| 2026-09-15 | WARRINGTON KENNETH HOWARD JR | +1,694 | - | - |
| 2026-09-15 | FORTUNATO MICHAEL A | -4,234 | - | - |
| 2026-09-15 | FORTUNATO MICHAEL A | +4,234 | - | - |
| 2026-09-15 | Matuszewski Jason | -8,469 | - | - |
| 2026-09-15 | Matuszewski Jason | +8,469 | - | - |
| 2026-09-09 | HASSETT BARRY | -500 | - | - |
| 2026-09-09 | HASSETT BARRY | +500 | - | - |
| 2026-08-27 | UNGRODT JODI | -5,647 | - | - |
| 2026-08-27 | UNGRODT JODI | +5,647 | - | - |
| 2026-08-27 | SONENREICH STEVEN D | -7,671 | - | - |
| 2026-08-27 | SONENREICH STEVEN D | +7,671 | - | - |
| 2026-08-27 | WARRINGTON KENNETH HOWARD JR | -5,094 | - | - |
| 2026-08-27 | WARRINGTON KENNETH HOWARD JR | +5,094 | - | - |
| 2026-08-27 | LESSER HANNAWAY RAYNA | -7,671 | - | - |
| 2026-08-27 | LESSER HANNAWAY RAYNA | +7,671 | - | - |
| 2026-08-27 | Glickman Mark A | -7,671 | - | - |
| 2026-08-27 | Glickman Mark A | +7,671 | - | - |
| 2026-08-11 | POE BRANDON | -10,634 | - | - |
| 2026-08-11 | POE BRANDON | +10,634 | - | - |
| 2026-08-09 | FORTUNATO MICHAEL A | -970 | - | - |
| 2026-08-09 | FORTUNATO MICHAEL A | +970 | - | - |